Phenomics Australia is leading Australia’s preclinical modelling capability deployment by convening national expertise and technology development exemplified by New Approach Methodologies (NAMs) that offer improved human-relevant therapeutic discovery and development tools.
NAMs technologies are evolving quickly in Australia and internationally to offer non-animal, cell- and computational-based model systems for fundamental discovery and therapeutic development.
Phenomics Australia CEO Professor Michael Dobbie and Dr Nathan Gödde (Australian Organoid Facility) represented national research infrastructure leadership at the AusBiotech International Conference 2026 satellite event, “New Approach Methods in Australian Biotech: Regulatory Science and Commercialisation”, organised with the Animal-Free Science Advocacy this week at the Gold Coast.
With active contributions from leaders in research, biotechnology, regulation, education, industry, ethics, advocacy and policy, the event explored how Australia can accelerate the development and adoption of NAMs and establish a National Collaborative Platform for NAMs.
Leading national collaboration and research infrastructure
Professor Michael Dobbie chaired the panel on national research infrastructure, covering resources including data, biobanking, and preclinical modelling services, highlighting the critical role of collaboration, shared resources and coordinated access to research capabilities in translating scientific innovation into practical outcomes.
His contribution reinforced the importance of strong national research infrastructure in enabling emerging technologies, connecting expertise across institutions and supporting the development of complementary experimental models that advance scientific discovery. With in vitro techniques gaining widespread adoption and national investment in Australia, there is a need for a balanced and informed approach that leverages the strengths of both animal and non-animal systems to enhance the effectiveness and translational value of therapeutic development.
Dr Nathan Gödde, Manager of Phenomics Australia’s node, the Australian Organoid Facility at The University of Queensland, contributed expertise in organoid technologies and their application in research. His participation showcased the importance of innovative model systems in advancing research approaches that reflect human biology.
Together, their involvement demonstrated Phenomics Australia’s leadership in connecting research expertise, infrastructure and emerging technologies to help shape Australia’s evolving research landscape.
From national ambition to practical implementation
The program explored key priorities for advancing NAMs in Australia, including building confidence and capability, navigating regulatory pathways, supporting commercialisation, strengthening education and workforce development, and coordinating national infrastructure.
A central theme was the need to move from strategic recommendations to practical implementation through sustained collaboration across Australia’s scientific community.
Phenomics Australia supports this vision and has contributed to CSIRO’s Non-animal models report, with partner scientists contributing expertise to inform a strategy recommending 10 actions to strengthen Australia’s non-animal model capabilities for medical product development.
Phenomics Australia is leading this effort by connecting researchers, supporting access to specialised research capabilities to build the collaborative foundations needed to accelerate the development and adoption of complementary next-generation experimental models.
Shaping the future of Australian research
Phenomics Australia is committed to working alongside researchers, institutions, industry, regulators, advocacy groups and government to strengthen Australia’s research capabilities and support scientific innovation.
By bringing together national expertise, enabling access to specialised infrastructure and championing collaboration, Phenomics Australia is helping lead the way in advancing emerging research technologies and supporting their translation into practice.






